UniQure stock falls after news of new CFO, acquisition, and new trial data

Shares of UniQure N.V., a Netherlands-based biotech with U.S. headquarters in Lexington, fell on Tuesday after three very different announcements involving a new top executive, an acquisition and new trial data. UniQure (Nasdaq: QURE) share prices were hovering around $30 as of 2:45 p.m., a decrease of more than 8%, giving the company a market cap of $1.4 billion. The company earlier in the day announced positive topline data from a Phase 3 study of its hemophilia B drug, etranacogene dezaparvovec,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news